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Abstract 36 
Background: Secondary bacterial infections are an important cause of morbidity and 37 
mortality associated with influenza infection. As bacterial disease can be caused by a 38 
disturbance of the host microbiome, we examined the impact of influenza on the upper 39 
respiratory tract microbiome in a human challenge study.  40 
Methods: The dynamics and ecology of the throat microbiome were examined following 41 
experimental influenza challenge of 52 previously healthy adult volunteers with Influenza 42 
A/Wisconsin/67/2005 (H3N2) by intranasal inoculation; 35 healthy control subjects were 43 
not subjected to viral challenge. Serial oropharyngeal samples were taken over a 30-day 44 
period, and the V1-V3 region of the bacterial 16S rRNA sequences were amplified and 45 
sequenced to determine the composition of the microbiome. The carriage of pathogens was 46 
also detected.  47 
Results: forty three of 52 challenged individuals developed proven influenza infection, of 48 
whom 33 became symptomatic. None of the controls developed influenza, although 22% 49 
reported symptoms. The diversity of bacterial communities remained remarkably stable 50 
following the acquisition of influenza, with no significant differences over time between 51 
individuals with influenza and those in the control group. Influenza infection was not 52 
associated with perturbation of the microbiome at the level of phylum or genus. There was 53 
no change in colonisation rates with Streptococcus pneumoniae or Neisseria meningitidis.  54 
Conclusions: The throat microbiota is resilient to influenza infection, indicating the 55 
robustness of the upper airway microbiome. 56 
 57 
 58 
Introduction 59 
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Secondary bacterial infection is a major cause of the mortality and morbidity associated with 60 
influenza virus [1]. Bacterial pneumonia caused millions of deaths during influenza pandemics 61 
in the 20th century [2], and remains a frequent complication following non-pandemic 62 
influenza. For example, 94% of a group of patients who died in the 1918 influenza pandemic 63 
demonstrated that all had evidence of secondary bacterial pneumonia [3], while 28% of 64 
fatalities in New York City associated with the 2009 H1N1 influenza pandemic had bacterial 65 
co-infection, with most only diagnosed post-mortem [4].  66 
 67 
Several pathogens cause bacterial infection following influenza. Co-infection with 68 
Haemophilus influenzae was so common that it was thought to cause influenza before the 69 
virus was isolated [5]. Streptococcus pneumoniae is now the commonest influenza-associated 70 
infection [6]. Cavitatory Staphylococcus aureus pneumonia is a severe influenza complication, 71 
and secondary pneumonia with MRSA emerged in the 2009 pandemic [7]. There is also an 72 
association between influenza A and systemic Neisseria meningitidis infection [8].  73 
 74 
Multiple mechanisms could explain bacterial disease following influenza. The virus is cytolytic 75 
and induces epithelial cell damage, impairment of surfactant production, and reduced muco-76 
ciliary clearance [9, 10]. Exposure of the epithelial basement membrane and extracellular 77 
matrix can offer binding sites for bacteria expressing matrix binding molecules [11]; glycan 78 
receptors for bacteria can be revealed by the activity of viral and bacterial neuraminidases 79 
(NA) [12, 13]. Additionally increased secretion of galectin 1 and galectin 3 can favour galectin-80 
mediated adhesion of S. pneumoniae and N. meningitidis [14]. Murine models indicate that 81 
host cell sialic acid released by NA can also act as a nutrient for pneumococcal growth in the 82 
upper airway, promoting bacterial spread to the lower airways [15].  83 
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 84 
The human microbiome is a complex community that has co-evolved with its host. A  healthy 85 
microbiota protects against invasion by pathogenic bacteria through a process referred to as 86 
colonisation resistance, in which the microbiota restricts growth or attachment of pathogens 87 
by competing for nutrients and ecological niches, or by direct antagonism [16].  88 
  89 
Several external factors influence the microbiome including age, smoking, and antibiotic 90 
treatment [17-19]. Furthermore changes in the microbiota are found with certain airway 91 
infections [20]. For example, healthy volunteers were reported to have a more diverse 92 
nasopharyngeal microbiome compared with patients suffering from pneumonia [21], while a 93 
highly diverse community is found in patients with asthma, cystic fibrosis, or Chronic 94 
Obstructive Pulmonary Disease [22, 23]. However, little is known about the impact of viral 95 
infection on the microbiota. No specific profile of bacteria in the URT was associated with 96 
seven different viral infections, although an apparent decrease in carriage of Haemophilus and 97 
Neisseria was observed after rhinovirus infection [24, 25].  98 
 99 
To further understand the cause of secondary bacterial infections, we investigated the impact 100 
of influenza virus on the human nasopharyngeal microbiome. We characterised the 101 
microbiota over a 30- day period in 52 healthy adults challenged with influenza A H3N2, and 102 
32 non-challenged individuals by using barcoded 454 pyrosequencing. This approach allowed 103 
us to define changes in the human microbiome following influenza challenge. Furthermore 104 
we examined whether influenza affected carriage of pathogens resident in the upper airways.   105 
  106 
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MATERIALS AND METHODS 107 
Study design  108 
The study took place in a secure quarantine facility with written informed consent from 109 
volunteers, in accordance with the Declaration of Helsinki, and in full compliance with the UK 110 
regulatory and ethical (IRB) requirements. 111 
 112 
Volunteers were screened before study entry to assess susceptibility to the challenge virus. 113 
In brief, volunteers were healthy with no acute or chronic medical condition, between the 114 
ages of 18 and 45, not living with anyone at risk of influenza complications, and not to have 115 
had a seasonal influenza vaccine in the last three years. Blood samples from volunteers were 116 
collected immediately before quarantine entry for antibody testing.  117 
 118 
Subjects were randomly allocated to challenge (n=52) or control groups (n=35) on day -1. On 119 
day 0, individuals in the challenge group were inoculated intranasally with a total of 5.5 log10 120 
TCID50/ml/nostril of influenza strain A/H3N2/Wisconsin/67/2005. The control group were not 121 
subjected to viral challenge (Figure 1).  122 
 123 
Clinical monitoring and sample collection 124 
Volunteers recorded symptoms daily, and vital signs were recorded three times daily. 125 
Nasopharyngeal (NPS) and oropharyngeal swabs, and venous blood were collected on days 126 
−1, 3, 6 and 28. Respiratory specimens were analysed by quantitative PCR and serological 127 
specimens by HAI and microneutralisation (MN) assays. Laboratory confirmed influenza was 128 
defined as: a 4-fold or greater rise in HAI or MN titres between day -2 and day 28, or a positive 129 
NPS test by PCR.  130 
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 131 
Volunteers were classified according to their symptoms and signs. ‘Influenza-like illness’ (ILI) 132 
was defined according to the CDC definition: an illness lasting ≥24 hours with either a 133 
temperature of > 37.9°C, or two or more symptoms, at least one of which was respiratory. 134 
Volunteers were ‘symptomatic’ if they experienced symptoms with no fever, experienced a 135 
single symptom, had ≥ two symptoms but none of which were respiratory, or had an illness 136 
of <24 hours. Therefore, a volunteer could have an ILI or be Symptomatic, and not be infected 137 
with influenza. Individuals were classified according to their symptomatology and tests into: 138 
ILIflu+, subjects who received viral challenge, and had an ILI with evidence of influenza infection 139 
(n=19); Sflu+, subjects who received viral challenge and were symptomatic with evidence of 140 
influenza infection (n=14); and ILI/Sflu+ includes individuals belonging to both these groups 141 
(n=33). Those not challenged with influenza, who remained asymptomatic/influenza negative 142 
formed the AC (Asymptomatic Control) group (n=24). 143 
 144 
DNA isolation and pyrosequencing 145 
DNA was extracted from swabs using the MoBio Power Soil isolation kit (MoBio laboratories). 146 
Barcoded primers were used to amplify ~ 500 bp V1-V3 region of the 16S rRNA gene as 147 
previously [26]. Amplification conditions were 5 minutes at 95°C, then 25 cycles of 95°C for 148 
45 seconds, 53°C for 45 seconds, 72°C for 1 minute 30 seconds with a final step of 72°C for 15 149 
minutes. The products were analyse using an Agilent 2100 Bioanalyzer after purification with 150 
the QIAquick kit (Qiagen). Quantitation was performed using Quant-iT Picogreen (Invitrogen). 151 
Samples were pooled at equimolar concentrations, and sequenced using a Roche 454 GS-FLX 152 
Titanium platform. 153 
 154 
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Sequence analysis 155 
The quality of sequences was assessed using FastQC v0.11.3 (Babraham Institute). Pre-156 
processing of sequences was performed with mothur v1.35.1 [27] based on the Schloss 157 
operating procedure. Next, trim.flows was used to remove sequences with mismatches in the 158 
primer sequence or the barcode. Sequences were de-noised by shhh.flows, trimmed to 159 
remove primers and barcodes, then aligned to the SILVA 16S rRNA reference alignment using 160 
trim.seqs; chimeric sequences were eliminated by Uchime [28]. Sequences were BLASTed 161 
against the Human Oral Microbiome Database v13.2 at the 98.5% sequence identity level. 162 
Sequences met the following criteria: read length >375 nt. (excluding barcode and primers), 163 
no ambiguous bases, or homopolymers of >8 nt. 164 
 165 
A sequence dissimilarity distance of 0.015 was used to cluster sequences into operational 166 
taxonomic units (OTUs), using the average neighbour algorithm. Taxonomies were assigned 167 
using the HOMD reference dataset. The richness of the microbial communities was calculated 168 
using Chao1 and Catchall indices [29, 30], and diversity estimated with Simpson’s inverse [31] 169 
and Shannon [32] indices. Good’s non-parametric estimator assessed coverage of 170 
communities in samples [33]. Species diversity between the samples was examined by 171 
analysing the beta diversity. Samples were adjusted to 2997 reads per sample by random 172 
sampling. Distance matrices were generated with the Jaccard Index and thetaYC measure of 173 
dissimilarity [34], and visualized by principal coordinate analysis (PCoA). Dendrograms 174 
representing relationships between samples were analysed by parsimony and UniFrac [35]. 175 
 176 
 177 
 178 
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S. pneumoniae and N. meningitidis carriage   179 
N. meningitidis was isolated by plating samples to GC selective medium. A 413 bp fragment 180 
encoding the 50S ribosomal protein L6 (RplF) was amplified by PCR, sequenced, and identified 181 
with PubMLST [36]. Meningococcal isolates were characterized by serogrouping, serotyping 182 
and serosubtyping. To detect the pneumococcus, qPCR of a region of lytA was performed 183 
using TaqMan (Thermo-Scientific) as previously [37]. 184 
 185 
Statistical analyses 186 
Analysis of alpha diversity was performed using Kruskal-Wallis test with Dunn’s correction for 187 
multiple comparisons was applied. Analysis of Molecular Variance (AMOVA) was used to 188 
evaluate differences between groups in PCoA [38]. Parsimony tests were implemented by 189 
mothur [39]. The Linear Discriminant Analysis (LDA) effect Size (LEfSe) was used to examine 190 
differences in Operational Taxonomic Units (OTUs) in the control/challenged groups [40]; the 191 
alpha values were set to 0.05 and a LDA score of 2.5 was selected. A two-tailed Fisher exact 192 
test was applied to compare colonization rates for pathogens.  193 
  194 
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RESULTS 195 
Infection and the development of symptoms after influenza challenge 196 
Although volunteers were screened for antibodies against influenza in advance, three 197 
individuals in the challenge group and three in the control group had serological evidence of 198 
prior H3N2 infection at study entry, so were excluded from subsequent analysis.  199 
 200 
Influenza infection was confirmed in 43 of the 52 individuals (82%) who subjected to influenza 201 
challenge; 33 subjects developed symptoms including 19 with ILI (ILIflu+). An additional three 202 
subjects were challenged with influenza and became symptomatic, but no evidence of 203 
influenza infection. Three other challenged individuals remained asymptomatic with no 204 
evidence of influenza.  205 
 206 
Characterisation of the pharyngeal microbiome  207 
A total of 2,505,196 sequences were obtained from 87 individuals (52 in the challenged group, 208 
and 35 controls) at four time points: day -1, 3, 6 and 28. DNA extraction failed for one sample, 209 
and amplification was unsuccessful from four samples, giving a total of 343 samples. Chimeric 210 
sequences were removed by alignment to the SILVA database, resulting in 2,057,548 211 
sequences.  212 
 213 
Initially we compared individuals who were symptomatic or had ILI with proven influenza 214 
infection from the challenged group (n=33) with asymptomatic individuals from the control 215 
group (n=24). To normalize the dataset, we took 2997 sequences from each sample; 11 216 
samples had fewer than 2997 sequences so were excluded, leaving a total of 213 samples. 217 
2209 OTUs (based on <98.5% of identity, > 4 representatives) were identified, with 24% of 218 
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sequences falling into only three OTUs: OTU1 (accounting for 9.78% of sequences), with 219 
predominant members Fusobacterium periodonticum, and OTU2 and OTU3 (7.8% and 7%, 220 
respectively), with the predominant members of both unclassified streptococci; OTU2 and 221 
OTU3 were identified as S. salivarus/S. vestibularis, and S. mitis/S. pneumoniae, respectively. 222 
 223 
Changes in the diversity of nasopharynx microbiota based on OTU analysis 224 
The coverage of bacterial communities was high (mean 97.6% ± 0.007%), with samples having 225 
an average of 161 OTUs (range 63 to 321). The mean number of OTUs at each time point was 226 
not significantly different between the groups (asymptomatic controls vs. ILI/Sflu+ p 0.4425, 227 
Figure 2A). Furthermore, the number of OTUs remained remarkably constant over time, even 228 
in the ILIflu+ and Sflu+ groups, with no significant difference compared with Asymptomatic 229 
controls (Supplementary Figures 1 and 2, p = 0.5543 and 0.5836, respectively).  The Chao 1 230 
index measures the predicted total richness of the community so gives a higher value (median 231 
of 262 OTUs, range 84 to 577 OTUs, Figure 2B) than the number of recorded OTUs; the non-232 
parametric estimator Catchall gave a median value of 437 OTUs per sample (range 66 to 233 
2643). Using these estimators, there were no significant differences in the richness of the 234 
between the ILI/Sflu+ group and Asymptomatic control groups (Figure 2B). Furthermore, there 235 
was no significant difference in the richness of microbial communities in symptomatic 236 
individuals even when we compared individuals in the ILI/Sflu+ group with asymptomatic 237 
controls (Supplementary Figures 1 and 2). 238 
 239 
We also estimated the diversity of bacterial communities using the Shannon index. Again no 240 
difference was detected between the challenged and control groups (Figure 2C, 241 
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Supplementary Figure 1 and 2), even when we analysed the diversity of the communities in 242 
highly symptomatic ILI subjects and the Asymptomatic controls (Supplementary Table 1).  243 
 244 
Next, we used beta diversity analysis to assess differences between samples. Dendrograms 245 
were generated highlighting similarities of the membership and structure of bacterial 246 
communities using Jaccard and thetaYC indices, respectively. At the four time points, results 247 
for certain individuals cluster together (e.g. individual Sflu+ individual 2, ILIflu+6, Sflu+7, Sflu+10, 248 
ILIflu+11, Sflu+12, ILIflu+13, Sflu+17, ILIflu+28, AC61, AC65), indicating that the individual had a 249 
stronger influence on microbiome than influenza. This was evidenced by samples from four 250 
different time points clustering together in the dendrogram (Supplementary Figure 43). No 251 
significant clustering of OTUs in the control or the influenza challenged groups, or over time 252 
was found when we applied a parsimony test. The thetaYC index, which considers the 253 
structure of communities by looking at the relative abundance of OTUs, yielded a complex 254 
dendrogram (Supplementary Figure 53). Although there were no large shifts in the 255 
communities, minor changes were detected when we applied a parsimony test with the 256 
clustering in the ILI/Sflu+ and Asymptomatic control groups slightly different on days 3, 6 and 257 
28 (p <0.02, p <0.024, and p <0.001, respectively). However these differences were not found 258 
after applying a Unifrac unweighted test. 259 
 260 
The community structure and membership of the oropharyngeal microbiota was visualized 261 
by PCoA (Figure 3). Small differences were found in the structure but not membership of 262 
communities in the ILI/Sflu+ group and Asymptomatic controls at day 3 and day 6 (p <0.035 263 
and p <0.033, respectively, Figure 3). This difference was also found when we compared Sflu+ 264 
individuals with Asymptomatic controls (p <0.001). The structure was also visualized for each 265 
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group separately (Supplementary Figure 3), where we found that day 6 post infection showed 266 
statistically significant difference compared to baseline within the ILI/Sflu+ group ( p <0.036), 267 
while in the Asymptomatic control group, days 3, 6 and 28 showed some statistically 268 
significant difference compared to baseline (p <0.001), indicating that the process of being in 269 
quarantine might have subtle effects on the URT microbiome.  270 
LEfSe analysis found that the abundance of some OTUs in these groups was significantly 271 
different on days 3 and day 6 post-infection (Figure 4). OTUs which are more abundant within 272 
the ILI/Sflu+ group at day 3 included OTU11 (Prevotella melaninogenica), OTU14 (Leptotrichia), 273 
OTU38 (Human Oral Taxon 352) and OTU38 (Porphyromonas), while OTU42 (Burkhordiales) 274 
and OTU6 (Leptotrichia HOT218) were more abundant within Asymptomatic control group. At 275 
day 6 OTU18 (Fusobacterium necrophorum) and OTU37 (Prevotella) were significantly more 276 
abundant in individuals in the ILI/Sflu+ group.  277 
 278 
Alteration in the ecology of the pharyngeal microbiome during influenza  279 
Next we examined the communities by phylum. Of 2,057,548 sequences, 19,416 could not be 280 
classified, while the remainder were distributed into 11 phyla, with 97% of them belonging to 281 
five phyla, Actinobacteria (7.9%), Fusobacteria (24.2%), Firmicutes (36.5%), Bacteroidetes 282 
(14.1%) and Proteobacteria (14.4%). We also detected Spirochaetes, Synergistetes, 283 
Tenericutes and GN02 together with members of two uncultured prokaryotes, TM7 and SR1, 284 
at < 1% of the total microbiota.  285 
 286 
The abundance of each phylum remained remarkably constant following influenza challenge 287 
with similar patterns seen across both groups. There was a significant change in the 288 
Bacteroidetes which increased in the ILI/Sflu+ group at day 3 post-infection compared to 289 
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Asymptomatic controls (Figure 5B). We also analysed how these phyla change over the time. 290 
Within the ILI/Sflu+ group there was a significant change in the abundance of Actinobacteria 291 
which increased by day 6 post infection compared to baseline (p <0.01), and returned to basal 292 
levels by day 28 (Supplementary Figure 6A5). 293 
Firmicutes were also increased between day 6 and 28 post infection in the control group 294 
(Supplementary Figure 6C), with an increase in Streptococcus (Supplementary Figure 7A), 295 
coinciding with individuals returning to the community so this might reflect changes in social 296 
behaviour.  297 
 298 
With regard to the composition at the genus level, Streptococcus was a core component of 299 
the microbiome, accounting for 21.8% of all bacteria, with Fusobacterium and Prevotella also 300 
abundant (comprising 15.4% and 9.9%, respectively). Neisseria, Haemophilus and 301 
Campylobacter each accounted for 2-5% of the microbiota (Figure 6). Differences were 302 
identified between the ILI/Sflu+ group and Asymptomatic controls (Figure 76), with a significant 303 
increase in relative abundance of Prevotella at day 3 and 28 post infection in the challenged 304 
group (p <0.05), and in Fusobacterium by day 28 post infection (p <0.05) (Figure 7C and 7B). 305 
Within the ILI/Sflu+ group, a minor increase in Actinomyces was observed at day 6 post infection 306 
(p <0.05) and in parallel Haemophilus decreased (p <0.01) (Supplementary Figure 8I and 8E6E 307 
and 6I). 308 
 309 
S. pneumoniae and N. meningitidis carriage is unaltered during influenza  310 
As 16S sequencing often cannot discriminate different species, we analysed carriage of two 311 
important respiratory pathogens, S. pneumoniae and N. meningitidis. The rate of colonization 312 
by encapsulated or non-encapsulated N. meningitidis was similar with no difference between 313 
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challenged and controls individuals (Figure 97). For S. pneumoniae 16 of 36 influenza 314 
challenged subjects (31%) and 12 of 23 controls (34%) were positive for S. pneumoniae using 315 
qPCR at day 3 (Fisher’s exact test p =0.8163).  316 
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DISCUSSION 317 
We performed the first prospective characterization of bacterial communities within the 318 
human URT during influenza infection. Previous studies have examined changes in the 319 
microbiota following challenge with other viruses [24, 25], and found only minor changes in 320 
the abundance of certain bacterial genera. Furthermore, cross-sectional studies have 321 
characterized the microbiome of patients with influenza [41]. However we are not aware of 322 
previous studies that have examined individuals following a defined influenza challenge.  323 
 324 
We detected only slight perturbations in the upper respiratory microbiota following challenge 325 
with influenza A. There was a high level of inter-individual variation in the upper respiratory 326 
microbiome, a common feature of studies on humans [26], and found that the microbiota 327 
contains at least 11 different phyla, with five phyla (Actinobacteria, Firmicutes, Fusobacteria, 328 
Bacterioidetes and Proteobacteria) constituting the core microbiome, similar to other studies 329 
[25]. Additionally Fusobacteria were highly prevalent (accounting for 24.2% of all OTUs), in 330 
agreement with previous work [19].  331 
 332 
The microbiota were dominated by Streptococcus and Fusobacterium, which include species 333 
that can cause influenza-associated pulmonary disease. However during the acquisition of 334 
influenza, the profile of the URT microbiome remained remarkably stable. Although we 335 
detected no large shift in the bacterial population at the genus level, there was a significant 336 
increase in the abundance of Prevotella in the ILI/Sflu+ group at days 3 and 28, a key time when 337 
secondary bacterial infection occurs; although P. melaninogenica was associated with this 338 
increase at day 3, little is known about its role in respiratory disease. 339 
 340 
16 
 
Overall, our study does not provide evidence that influenza infection has a marked impact in 341 
shaping the pharyngeal microbiome. However, certain factors might be responsible for the 342 
lack of effect we observed. Participants were healthy adults, who do not generally suffer 343 
secondary bacterial infection; studies in at-risk individuals might reveal more significant 344 
changes in the microbiome, although pose a serious ethical and safety dilemma. In addition, 345 
effects might have become evident using a larger study population. Furthermore, 16S rRNA-346 
based methods are limited and lack species-level resolution for particular genera, including 347 
Streptococcus and Neisseria. Even though cohort studies have established a relationship 348 
between influenza and the rate of pneumococcal carriage, we did not find any difference in 349 
pneumococcal carriage following influenza infection. For the meningococcus, we also 350 
examined capsule expression, as this virulence factor is only expressed by a sub-set of strains 351 
[42]. However, there was no alteration in the rate of carriage of either encapsulated or non-352 
encapsulated N. meningitidis in our cohort with the advent of influenza infection. We did not 353 
examine swabs for the presence of S. aureus, as this is a far less frequent secondary bacteria 354 
pathogen following influenza than S. pneumoniae, and is associated with severe disease, and 355 
not milder forms of infection such as represented by this challenge model. 356 
 357 
In conclusion, our findings demonstrate that the upper airway microbiota is not 358 
reprogrammed by acquisition of influenza, with only minor perturbations seen in bacterial 359 
communities. Further studies are required to examine the cross-kingdom interactions that are 360 
responsible for secondary bacterial infection being a key player in the mortality and morbidity 361 
associated with influenza.  362 
 363 
  364 
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FIGURE LEGENDS 506 
 507 
Figure 1. Study timeline.  508 
Volunteers were screened prior to admission to a quarantine unit on the day before receiving 509 
an intranasal challenge of Influenza A (on day 0), then followed for 28 days. The volunteers 510 
were kept in quarantine for six days post inoculation. Controls were screened and housed in 511 
identical conditions, but were not subjected to viral challenge.  Throat swabs were collected 512 
at different time points during the study (i.e. on days -1, 3, 6 and 28 post-inoculation).   513 
 514 
Figure 2. Analysis of the richness of the URT microbiome.  515 
The diversity of the microbiome was analysed by sequencing the V1-3 region of 16SrRNA 516 
amplified from samples obtained from the ILI/Sflu+ (white boxes) and Asymptomatic control 517 
(grey boxes) groups following influenza A challenge. The box whisker plots extend from 25
th
 518 
to 75
th
 percentiles, and the ends of the whiskers show the maximum and minimum values. 519 
The line in the middle of the box represents the median and the dots represent the outliers 520 
1.5 greater or lower than the interquartile distance. Analysis was based on: (A) the number of 521 
OTUs; (B) Chao1 index; and (C) Shannon diversity index at baseline, 3 (3dpi), 6 (6dpi) and 28 522 
(28dpi) days post influenza challenge. 523 
 524 
Figure 3. Throat microbiota structure in ILI/Sflu+ and Asymptomatic control groups during 525 
influenza challenge. PCoA based on the Thetayc index comparing community structure of 526 
samples from ILI/Sflu+  infected group (blue open circles) and Asymptomatic control (red open 527 
circles) groups at days 3 (A), and day 6 (B). The centroid represents the arithmetic mean for 528 
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each of the groups and each dot represents the microbiota structure profile for each of the 529 
samples, while the ellipses represent the 95% of the samples belonging to each group. 530 
 531 
Figure 4. LEfSe analysis of abundant OTUs in ILI/S
flu+ 
and Asymptomatic controls.  532 
The positive scale indicates the LDA score (Log10) for the most abundant taxa in the ILI/Sflu+ 533 
group (green bars), while the negative scale represents LDA scores for prevalent taxa in the 534 
Asymptomatic control group on days 3 (A) and 6 (B).  535 
 536 
Figure 5. Relative abundance of common phyla in the human oropharynx.  537 
Comparison of tThe abundance of each phylum betweenin individuals (open squares) in the 538 
ILI/Sflu+ group (+), and the Asymptomatic controls (-). The phyla are indicated in each panel. 539 
Error bars represent the standard deviation error of the mean (SDSEM). Non-parametric 540 
Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant 541 
differences in relative abundance between groups: *, p <0.05; **, p <0.01. Samples are from 542 
individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge, or not 543 
(in the control group).  544 
 545 
Figure 6. Relative abundance of common phyla in the human oropharynx.  546 
The abundance of each phylum in individuals within the ILI/Sflu+ group (+). The phyla are 547 
indicated in each panel. Error bars represent the standard deviation (SD). Non-parametric 548 
Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant 549 
differences in relative abundance between groups: *, p <0.05; **, p <0.01. Samples are from 550 
individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge.   551 
 552 
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 553 
Figure 76. Relative abundance of the common genera in the human oropharynx.  554 
Comparison of tThe abundance of each phylum in individuals (open squares) betweenin the 555 
ILI/Sflu+ group (+), and the Asymptomatic controls (-). generaGenera are indicated in each 556 
panel. Error bars represent the standard error of the meandeviation (SDSEM). Non-parametric 557 
Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant 558 
differences in relative abundance between groups: *, p <0.05; **, p <0.01. Samples are from 559 
individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge, or not 560 
(in the control group).  561 
 562 
Figure 8. Relative abundance of the common genera in the human oropharynx.  563 
The abundance of each genera in individuals within the ILI/Sflu+ group (+). The genera are 564 
indicated in each panel. Error bars represent the standard deviation (SD). Non-parametric 565 
Kruskal-Wallis test for multiple comparisons was applied to identify statistically significant 566 
differences in relative abundance between groups: *, p <0.05; **, p <0.01. Samples are from 567 
individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge.   568 
 569 
 570 
 571 
Figure 97.  N. meningitidis carriage following influenza challenge.  572 
Meningococcal carriage in the ILI/S
flu+ 
group (A) and in the Asymptomatic control group (B) at 573 
different times following challenge. Carriage of non-groupable N. meningitidis was unchanged 574 
during influenza, and ranged between 11.4 and 13.5 % except for controls from day 6 and 28. 575 
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There was no change in the carriage of groupable N. meningitidis over time or between 576 
groups.  577 
 578 
 579 
  580 
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SUPPORTING INFORMATION 581 
 582 
Supplementary Figure 1. Richness measurements of the ILIflu+ and Asymptomatic control 583 
groups following influenza A challenge.  584 
The box whisker plots extend from 25
th
 to 75
th
 percentiles and the ends of the whiskers show 585 
the maximum and minimum values. The line in the middle of the box represents the median 586 
and the dots represent the outliers being 1.5 greater or lower than the interquartile distance. 587 
(A) Number of OTUs, (B) Chao1 index and (C) the Shannon diversity index at baseline (B), and 588 
3 (3dpi), 6 (6dpi), and 28 (28dpi) days after the influenza challenge. 589 
 590 
 Supplementary Figure 2. Richness measurements of the Sflu+ and Asymptomatic control 591 
groups following influenza challenge.  592 
The box whisker plots extend from the 25
th
 to 75
th
 percentiles and the ends of the whiskers 593 
show the maximum and minimum values. The line in the middle of the box represents the 594 
median and the dots represent the outliers, 1.5 greater or lower than the interquartile 595 
distance. (A) Number of OTUs, (B) Chao1 index, and (C) the Shannon diversity index at baseline 596 
(B), 3 (3dpi), 6 (6dpi) and 28 (28dpi) days after the influenza challenge. 597 
 598 
Supplementary  Figure 3. Throat microbiota structure in ILI/Sflu+ and Asymptomatic control 599 
groups during influenza challenge. PCoA based on the Thetayc index comparing community 600 
structure of samples within ILI/Sflu+  infected group (A) and Asymptomatic control (B) groups 601 
at Baseline (purple), day 3 (green) day 6 (blue) and day 28 after challenge (red). Each dot 602 
represents the microbiota structure profile for each of the samples, while the ellipses 603 
represent the 95% of the samples belonging to each group. 604 
26 
 
 605 
 606 
 607 
Supplementary Figure 43. Dendrograms of throat communities in ILI/Sflu+ and 608 
Asymptomatic control groups during an influenza challenge.   609 
Clustering of throat samples at different time points of an influenza challenge compared 610 
based on their community membership by using classical Jaccard Index. AC = Asymptomatic 611 
Control, ILI
flu+ 
= subjects who received viral challenge and had an ILI with evidence of influenza 612 
infection, S
flu+
 = subjects who received viral challenge and were Symptomatic with evidence 613 
of influenza infection, B = baseline, 3dpi = 3 days post infection, 6dpi = 6 days post infection, 614 
28dpi = 28 days post infection. Numbers indicate subject or patient number. 615 
 616 
Supplementary Figure 54. Dendrograms of throat communities in ILI/Sflu+ and 617 
Asymptomatic control groups during an influenza challenge.  618 
(A) Clustering of throat samples at different time points of an influenza challenge compared 619 
based on their community structure by using classical Thetayc. AC = Asymptomatic Control, 620 
ILI
flu+ 
= subjects who received viral challenge and had an ILI with evidence of influenza 621 
infection, S
flu+
 = subjects who received viral challenge and were Symptomatic with evidence 622 
of influenza infection, B = baseline, 3dpi = 3 days post infection, 6dpi = 6 days post infection, 623 
28dpi = 28 days post infection. Numbers indicate subject or patient number. 624 
 625 
Supplementary Figure 65. Relative abundance of common phyla in the human oropharynx.  626 
27 
 
The abundance of each phylum in individuals within the Asymptomatic controlILI/Sflu+ group 627 
over time. The phyla are indicated in each panel. Error bars represent the standard deviation 628 
(SD). Non-parametric Kruskal-Wallis test for multiple comparisons with a Dunn’s post test 629 
coreectioncorrection was applied to identify statistically significant differences in relative 630 
abundance between groups: *, p <0.05; **, p <0.01, ***; p <0.001. Samples are from 631 
individuals prior on entry to quarantine (baseline), and days 3, 6 and 28 after challenge. 632 
 633 
Supplementary Figure 76. Relative abundance of the common genera in the human 634 
oropharynx.  635 
 636 
The abundance of each phylum in individuals within the Asymptomatic controlILI/Sflu+ group 637 
over time. The genera are indicated in each panel. Error bars represent the standard deviation 638 
(SD). Non-parametric Kruskal-Wallis test with a Dunn’s post test correction was applied to 639 
identify statistically significant differences in relative abundance between groups: *, p <0.05; 640 
**, p <0.01, ***; p <0.001. Samples are from individuals prior on entry to quarantine 641 
(baseline), and days 3, 6 and 28 after challenge. 642 
 643 
 644 
Supplementary  Figure 7. Throat microbiota structure in ILI/Sflu+ and control groups during 645 
influenza challenge. PCoA based on the Thetayc index comparing community structure of 646 
samples within ILI/Sflu+  infected group (A) and Asymptomatic control (B) groups at Baseline 647 
(purple), day 3 (green) day 6 (blue) and day 28 after challenge (red). Each dot represents the 648 
microbiota structure profile for each of the samples, while the ellipses represent the 95% of 649 
the samples belonging to each group. 650 
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 651 
Supplementary Table 1. Alpha diversity of ILI/Sflu+ and control groups. 652 
